Similar articles

• 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.

  Torres A, Niemeyer A, Berkes B, Marra D, Schanbacher C, González S, Owens M, Morgan B. Torres A, et al. Dermatol Surg. 2004 Dec;30(12 Pt 1):1462-9. doi: 10.1111/j.1524-4725.2004.30504.x. Dermatol Surg. 2004. PMID: 15606733 Clinical Trial.
• Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study.

  Butler DF, Parekh PK, Lenis A. Butler DF, et al. Dermatol Surg. 2009 Jan;35(1):24-9. doi: 10.1111/j.1524-4725.2008.34378.x. Epub 2008 Nov 19. Dermatol Surg. 2009. PMID: 19018814 Clinical Trial.
• Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.

  van der Geer S, Martens J, van Roij J, Brand E, Ostertag JU, Verhaegh ME, Neumann HA, Krekels GA. van der Geer S, et al. Br J Dermatol. 2012 Jul;167(1):110-5. doi: 10.1111/j.1365-2133.2012.10924.x. Epub 2012 May 21. Br J Dermatol. 2012. PMID: 22385074 Clinical Trial.
• Escharotic and other botanical agents for the treatment of skin cancer: a review.

  Jellinek N, Maloney ME. Jellinek N, et al. J Am Acad Dermatol. 2005 Sep;53(3):487-95. doi: 10.1016/j.jaad.2005.04.090. J Am Acad Dermatol. 2005. PMID: 16112359 Review. No abstract available.
• Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.

  Papakostas D, Stockfleth E. Papakostas D, et al. Future Oncol. 2015 Nov;11(22):2985-90. doi: 10.2217/fon.15.192. Epub 2015 Oct 9. Future Oncol. 2015. PMID: 26450707 Review.